- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
Scientists Find Clue to Links Between Autism, Epilepsy
Kids with autism have low levels of a protein that quiets overactive brain cells, which may explain why so many have epilepsy, according to a new study.
Because the protein can be detected in cerebrospinal fluid, it may have promise as a marker to diagnose autism and as a potential treatment target for the epilepsy that sometimes accompanies it, according to Northwestern University researchers.
The protein pinpointed in this study — called CNTNAP2, or “catnap2” — is produced by the brain cells when they become overactive. Because the brains of kids with autism and epilepsy don’t have enough of it, their brains don’t calm down, which leads to seizures, the study authors explained.
“We can replace CNTNAP2,” said lead study author Peter Penzes, director of the Center for Autism and Neurodevelopment at Northwestern’s Feinberg School of Medicine, in Chicago. “We can make it in a test tube and should be able [to] inject it into children’s spinal fluid, which will go back into their brain.”
For the study, the researchers analyzed cerebrospinal fluid from people with autism and epilepsy, and from mice. Levels of the protein in cerebrospinal fluid help determine levels in the brain.
The findings, published online Dec. 17 in the journal Neuron, could lead to new treatments, the study authors suggested in a university news release.
Penzes and his team are now conducting preclinical research on the injection technique.
While cerebrospinal fluid from patients with Alzheimer’s and Parkinson’s has been analyzed to help diagnose disease and assess response to treatment, the researchers said this is the first such study in people with autism.
In the United States, autism affects one in 58 children, and 30% to 50% of them also have epilepsy.
More information
The Autism Research Institute has more on autism and seizures.
SOURCE: Northwestern University, news release, Dec. 17, 2021
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.